Insights into pathophysiology, biomarkers, and therapeutics in tauopathies: Proceedings of the Tau2024 Global Conference

Recent years have seen major advances in tau-associated brain disorders through interdisciplinary research spanning molecular biology, neuroimaging, clinical trials, and therapeutic development. The Tau2024 Global Conference, hosted by the Alzheimer's Association, CurePSP, and Rainwater Charitable Foundation, showcased these efforts by bringing together researchers and experts worldwide to discuss the latest advancements in tau research. The conference aimed to attract talent and funding to study tauopathies, particularly among early-career researchers, and to foster interdisciplinary alignment and collaboration around challenges in tau research. In this manuscript, we summarize proceedings of the Tau2024 Global Conference, covering a wide range of topics, including lived experiences of individuals with genetic forms of tauopathies, global perspectives on tauopathies, and molecular mechanisms, brain microenvironments, biomarker developments, clinical trials, and therapeutic approaches to tauopathies. Through international, collaborative efforts, innovative research, and a commitment to inclusivity, researchers worldwide have demonstrated transformative breakthroughs toward diagnosing, treating, and, ultimately, preventing tau-related diseases. HIGHLIGHTS: The Tau2024 Global Conference presented updates and advances in tau research. Blood-based biomarkers offer specificity and longitudinal monitoring capabilities. There are a range of targetable mechanisms in the cascade of pathogenesis. International collaboration is vital to address disparities in tauopathies.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2025-05-01
DOI
https://doi.org/10.1002/alz.70078
Citations
3
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
3.49

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Insights into pathophysiology, biomarkers, and therapeutics in tauopathies: Proceedings of the Tau2024 Global Conference

Amy Rommel, David Butler, Simin Mahinrad, Jose F. Abisambra et al.
3 citations
Alzheimer s & Dementia
Alzheimer's disease research and treatments
3.49
article

Insights into pathophysiology, biomarkers, and therapeutics in tauopathies: Proceedings of the Tau2024 Global Conference

Amy Rommel, David Butler, Simin Mahinrad, Jose F. Abisambra, Colin Ewen, Ravi Yadav, Maura Malpetti, Susanne Wegmann, Rebecca M. Edelmayer, Boon Lead Tee, Kristin R. Wildsmith, Tim J. Viney, Agustín M. Ibáñez, Igor C. Fontana, Rufus Akinyemi, James B. Rowe, María C. Carrillo, Linde Jacobs, Claire E. Sexton, Mahmoud Bukar Maina, Bess Frost, Miranda E. Orr, Oskar Hansson, Luc Buée, Marie‐Christine Galas, Laia Montoliu‐Gaya, William A. McEwan, Eric McDade, Günter U. Höglinger, Jonathan D. Rohrer, Catherine J. Mummery, Peter S. Chung, Ratnavalli Ellajosyula, Matthias Brendel, Sarah L. DeVos, Jamie M. Walker, Fanny M. Elahi, Kristophe Diaz, Claire D. Clelland, Kanta Horie, Tara L. Spires‐Jones, Nicholas J. Ashton, Carlos Sastre
article en
3 citations

Abstract

Recent years have seen major advances in tau-associated brain disorders through interdisciplinary research spanning molecular biology, neuroimaging, clinical trials, and therapeutic development. The Tau2024 Global Conference, hosted by the Alzheimer's Association, CurePSP, and Rainwater Charitable Foundation, showcased these efforts by bringing together researchers and experts worldwide to discuss the latest advancements in tau research. The conference aimed to attract talent and funding to study tauopathies, particularly among early-career researchers, and to foster interdisciplinary alignment and collaboration around challenges in tau research. In this manuscript, we summarize proceedings of the Tau2024 Global Conference, covering a wide range of topics, including lived experiences of individuals with genetic forms of tauopathies, global perspectives on tauopathies, and molecular mechanisms, brain microenvironments, biomarker developments, clinical trials, and therapeutic approaches to tauopathies. Through international, collaborative efforts, innovative research, and a commitment to inclusivity, researchers worldwide have demonstrated transformative breakthroughs toward diagnosing, treating, and, ultimately, preventing tau-related diseases. HIGHLIGHTS: The Tau2024 Global Conference presented updates and advances in tau research. Blood-based biomarkers offer specificity and longitudinal monitoring capabilities. There are a range of targetable mechanisms in the cascade of pathogenesis. International collaboration is vital to address disparities in tauopathies.

Alzheimer s & DementiaVol. 21(5)
University of Southern California (US), Alzheimer's Association (US), Centre National de la Recherche Scientifique (FR), University of Arizona (US), Inserm (FR), University of Sussex (GB), Manipal Academy of Higher Education (IN), German Cancer Research Center (DE), University of California, San Francisco (US), University of Ibadan (NG), Lund University (SE), MRC Cognition and Brain Sciences Unit (GB), Washington University in St. Louis (US), Trinity College Dublin (IE), Adolfo Ibáñez University (CL), Heidelberg University (DE), Université de Lille (FR), University of Cambridge (GB), Brown University (US), German Center for Neurodegenerative Diseases (DE), Cambridge University Hospitals NHS Foundation Trust (GB), Centre Hospitalier Universitaire de Lille (FR), LMU Klinikum (DE), Yobe State University (NG), University of Florida (US), University of Oxford (GB), Rainwater Charitable Foundation (US), CurePSP (US), Ferrer Grupo (Spain) (ES), University Memory and Aging Center (US), Neural Stem Cell Institute (US), Munich Cluster for Systems Neurology (DE), James J. Peters VA Medical Center (US), UK Dementia Research Institute (GB), UCB Pharma (United Kingdom) (GB), Banner Sun Health Research Institute (US), Eisai (United States) (US), Global Brain Health Institute (US), Einstein Center for Neurosciences Berlin (DE), Manipal Hospital (IN), University College London (GB), Wake Forest University (US), National Institute of Mental Health and Neurosciences (IN), Charité - Universitätsmedizin Berlin (DE), Ludwig-Maximilians-Universität München (DE), University of Gothenburg (SE), Salisbury University (US), University of Edinburgh (GB), Icahn School of Medicine at Mount Sinai (US)
National Science Foundation, Foundation for the National Institutes of Health, U.S. Department of Veterans Affairs, Michael J. Fox Foundation for Parkinson's Research, Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Eli Lilly and Company, AstraZeneca, GlaxoSmithKline, Biogen, Cure Alzheimer's Fund, CurePSP, Wellcome Trust, PSP Association, Coins for Alzheimer's Research Trust, Innovationsfonden, EU Joint Programme – Neurodegenerative Disease Research, Ionis Pharmaceuticals, Chan Zuckerberg Initiative, Global Brain Health Institute, Université de Lille, Rainwater Charitable Foundation, Alzheimer's Society, Denali Therapeutics, Sangamo Therapeutics, Agenția Națională pentru Cercetare și Dezvoltare, Alzheimer's Research Trust, National Institute for Health and Care Research, European Commission, University of Sussex, Deutsche Forschungsgemeinschaft, Agence Nationale de la Recherche, Institut National de la Santé et de la Recherche Médicale, Fonds Wetenschappelijk Onderzoek, Eisai, Vetenskapsrådet, Centre National de la Recherche Scientifique, African Academy of Sciences, Vlaamse regering, UK Dementia Research Institute, Agencia Nacional de Investigación y Desarrollo, National Institutes of Health, University of California, San Diego, University of California, San Francisco, Medical Research Council, National Institute on Aging, National Institute of General Medical Sciences, Fogarty International Center, National Institute of Neurological Disorders and Stroke, Fondo Nacional de Desarrollo Científico y Tecnológico, Fondo de Fomento al Desarrollo Científico y Tecnológico, Fondo de Financiamiento de Centros de Investigación en Áreas Prioritarias, CHIST-ERA
Partnerships for the goals
Openalex Percentile: Top 8%
Alzheimer's disease research and treatments
3.49
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.